

**GENETIC POLYMORPHISM OF  
CATECHOL-O-METHYLTRANSFERASE  
AND KARYOTYPING ABNORMALITIES IN  
MENTALLY RETARDED CHILDREN**

**Thesis**

**Submitted for Complete Fulfillment of  
The Doctorate (M.D.) degree in  
Clinical and Chemical Pathology**

**By**

***RASHA ADEL YASSIN***

**(M.B., B.Ch.; M Sc.)**

**Under Supervision**

**Prof. Dr. Aisha Moustafa Abd El-Rahman**

*Professor of Clinical and Chemical Pathology,  
Faculty of Medicine, Cairo University*

**Prof. Dr. Sawsen Mohamed Abd El-Hady**

*Professor of Pediatrics,  
Faculty of Medicine, Cairo University*

**Prof. Dr. Amal Mahmoud Mohamed**

*Professor of Cytogenetics,  
National Research Institute*

**Prof. Dr. Hoda Mohamed Abd El-Ghany**

*Professor of Clinical and Chemical Pathology,  
Faculty of Medicine, Cairo University*

**Faculty of Medicine,  
Cairo University**

**2012**



## ACKNOWLEDGEMENT

*I would like to express my sincere thanks and deepest gratitude to **Prof. Dr. Aisha Moustafa Abd El-Rahman**, Professor of Clinical and Chemical Pathology, Faculty of Medicine, Cairo University, for her encouragement and her continuous guidance and valuable advice for enriching this work.*

*I am also grateful to **Prof. Dr. Hoda Mohamed Abd-El-Ghany**, Professor of Clinical and Chemical Pathology, Faculty of Medicine, Cairo University, for her valuable advice, encouragement throughout the entire study, cooperative attitude and creative suggestions.*

*I would like to express my sincere thanks and deep gratitude to **Prof. Dr. Sawsen Mohamed Abd El-Hady**, Professor of Pediatrics, Faculty of Medicine, Cairo University, for her energetic follow-up with constructive advice, criticism and creative suggestions.*

*I would like to express my sincere thanks and deep gratitude to **Prof. Dr. Amal Mahmoud Mohamed**, Professor of Cytogenetics, National Research Institute, for her valuable help and continuous support. Her remarks and advice undoubtedly aided in improving this work.*

*Finally, most thanks to my family especially my husband who supported me during preparation of this work.*

## CONTENTS

	Page
▪ Introduction .....	1
▪ Aim of the Work .....	3
▪ Review of Literature .....	4
○ Chapter 1: Mental Retardation .....	4
○ Chapter 2: Genetic Causes of Mental Retardation .....	49
○ Chapter 3: Catechol-O-Methyltransferase .....	67
▪ Patients and Methods .....	80
▪ Results .....	100
▪ Discussion .....	156
▪ Future Considerations .....	167
▪ Summary .....	168
▪ References .....	170
▪ Arabic Summary .....	185

## LIST OF FIGURES

No.	Title	Page
1	<b>Overview of causes of mental retardation.</b>	13
2	<b>Down syndrome.</b>	51
3	<b>Karyotyping of Down syndrome.</b>	52
4	<b>Edward syndrome.</b>	53
5	<b>Karyotyping of Edward syndrome.</b>	53
6	<b>Patau's syndrome.</b>	54
7	<b>Robertsonian translocation.</b>	56
8	<b>Williams-Beuren syndrome.</b>	58
9	<b>Karyotyping of Smith-Magenis syndrome.</b>	59
10	<b>Karyotyping of Fragile X-syndrome.</b>	64
11	<b>Fragile X-syndrome.</b>	65
12	<b>Reaction mechanism of COMT.</b>	67
13	<b>Sex distribution among the studied groups.</b>	101
14	<b>Percentage for the presence of different dysmorphic features in the studied groups.</b>	124
15	<b>karyotyping by conventional GTG banding for studied patients.</b>	128
16	<b>Case no (4): Normal male karyotype by conventional GTG banding: 46, XY.</b>	130
17	<b>Case no (9): Normal female karyotype by conventional GTG banding: 46, XX.</b>	131
18	<b>Frequency of COMT genotypes in the studied patients.</b>	134
19	<b>Gel electrophoresis of COMT Val 158 Met.</b>	136
20	<b>Gel electrophoresis of COMT Val 158 Met.</b>	137
21	<b>Sex distribution in different COMT genotypes.</b>	138
22	<b>Consanguinity among different COMT genotypes.</b>	139
23	<b>COMT genotypes and karyotyping analysis of the studied patients.</b>	142
24	<b>A three generation pedigree for case no (11).</b>	144
25	<b>Karyotyping by conventional GTG banding for case no (11): 46, XY, del(Y)(p11).</b>	145
26	<b>A three generation pedigree for case no (16) with a similar affection in his younger brother.</b>	146

<b>No.</b>	<b>Title</b>	<b>Page</b>
<b>27</b>	<b>Karyotyping by conventional GTG banding for case no (16): 47, XY, + Marker chromosome.</b>	<b>147</b>
<b>28</b>	<b>A three generation pedigree for case no (21).</b>	<b>148</b>
<b>29</b>	<b>Karyotyping by conventional GTG banding for case no (21): 47, XX + Marker chromosome.</b>	<b>149</b>
<b>30</b>	<b>A three generation pedigree for case no (27).</b>	<b>150</b>
<b>31</b>	<b>Karyotyping by conventional GTG banding for case no (27) :46, XY, dup(22)(p11).</b>	<b>151</b>
<b>32</b>	<b>A three generation pedigree for case no (33).</b>	<b>152</b>
<b>33</b>	<b>Karyotyping by conventional GTG banding for case no (33): 46, XX, del(9)(p22p24).</b>	<b>153</b>

## LIST OF TABLES

No.	Title	Page
1	<b>ICD-9-CM classification of mental retardation.</b>	<b>10</b>
2	<b>ICD-10 coding for mental retardation.</b>	<b>12</b>
3	<b>Risk Factors for Mental Retardation.</b>	<b>19</b>
4	<b>Selected clinical findings or laboratory abnormalities suggesting a metabolic disorder.</b>	<b>34</b>
5	<b>Primary prevention.</b>	<b>38</b>
6	<b>Overview of the types of genetic causes of mental retardation.</b>	<b>49</b>
7	<b>Groups of the studied patients according to IQ level.</b>	<b>100</b>
8	<b>Sex distribution among the studied groups.</b>	<b>101</b>
9	<b>Relation between family history of mental retardation and IQ levels among the studied groups.</b>	<b>102</b>
10	<b>Antenatal, natal and postnatal history in the studied patients.</b>	<b>103</b>
11	<b>Data concerning history of all cases.</b>	<b>104</b>
12	<b>Relation of consanguinity and IQ level among the studied groups.</b>	<b>105</b>
13	<b>Collective analysis of dysmorphic features of eyes and eyebrows in the studied patients.</b>	<b>106</b>
14	<b>Descriptive analysis of dysmorphic features of eyes and eye brows in the studied patients.</b>	<b>107</b>
15	<b>Collective analysis of dysmorphic features of the nose in the studied patients.</b>	<b>108</b>
16	<b>Descriptive analysis of dysmorphic features of nose in the studied patients.</b>	<b>109</b>
17	<b>Collective analysis of dysmorphic features of the mouth and skin in the studied patients.</b>	<b>110</b>
18	<b>Descriptive analysis of dysmorphic features of mouth and chin in the studied patients.</b>	<b>111</b>
19	<b>Collective analysis of dysmorphic features of ears in the studied patients.</b>	<b>112</b>
20	<b>Descriptive analysis of dysmorphic features of ears in the studied patients.</b>	<b>113</b>

No.	Title	Page
21	Collective analysis of dysmorphic features of hand, foot and skeletal system in the studied patients.	114
22	Descriptive analysis of dysmorphic features of the hand, foot and skeletal system in the studied patients.	115
23	Collective analysis of neuropsychiatric disorders in the studied patients.	116
24	Descriptive analysis of neurological manifestations in the studied patients.	117
25	Descriptive analysis of gastrointestinal manifestations in the studied patients.	119
26	Summary of clinical data of the studied patients.	120
27	Relation of Dysmorphic features and IQ level of the studied groups.	122
28	Collective clinical data of the studied patients.	125
29	Collective analysis of karyotyping by conventional GTG banding for studied patients.	127
30	Descriptive analysis of karyotyping by conventional GTG banding in the studied patients.	129
31	Karyotyping results among the studied groups.	132
32	Frequency of COMT genotypes in the studied patients.	133
33	COMT genotypes in the studied patients.	135
34	Sex distribution in different COMT genotypes.	138
35	Consanguinity among different COMT genotypes.	139
36	IQ level among patients with normal and mutant COMT genotypes.	140
37	IQ mean value in different COMT genotypes.	141
38	COMT genotypes and karyotyping analysis of the studied patients.	142
39	Collective laboratory data of the studied patients.	143
40	Descriptive data of cases with chromosomal abnormalities (cases no 11, 16, 21, 27 and 33).	154

## ABBREVIATIONS

<b>AACAP</b>	:	<b>American Academy of Child and Adolescent Psychiatry</b>
<b>AAIDD</b>	:	<b>American Association of Intellectual and Developmental Disabilities</b>
<b>AAMR</b>	:	<b>American Association of Mental Retardation</b>
<b>ABS</b>	:	<b>Adaptive behavior scale</b>
<b>APA</b>	:	<b>American Psychiatric Association</b>
<b>ARC</b>	:	<b>Association of Retarded Citizens</b>
<b>BSID</b>	:	<b>Bayley scales of infant development</b>
<b>CI</b>	:	<b>Confidence interval</b>
<b>CM</b>	:	<b>Clinical modifications</b>
<b>CNS</b>	:	<b>Central nervous system</b>
<b>COMT</b>	:	<b>Catechol-O-methyltransferase</b>
<b>CT</b>	:	<b>Computerized tomography</b>
<b>CVS</b>	:	<b>Cardiovascular system</b>
<b>DD/MR</b>	:	<b>Developmental delay/mental retardation</b>
<b>DA</b>	:	<b>Dopamine</b>
<b>DOMA</b>	:	<b>3,4-dihydroxymandetic acid</b>
<b>DQ</b>	:	<b>Developmental quotient</b>
<b>DSM</b>	:	<b>Diagnostic and statistical manual of mental disorders</b>
<b>EEG</b>	:	<b>Electroencephalography</b>
<b>ESAC</b>	:	<b>Extra Structurally Abnormal Chromosome</b>
<b>FISH</b>	:	<b>Fluorescence in situ hybridization</b>
<b>FMR-1</b>	:	<b>Fragile-X mental retardation-1 gene</b>
<b>FRAX</b>	:	<b>Fragile X syndrome</b>
<b>GDD</b>	:	<b>Global developmental delay</b>
<b>GIT</b>	:	<b>Gastrointestinal tract</b>
<b>HCG</b>	:	<b>Human chorionic gonadotropin</b>
<b>HPLC</b>	:	<b>High performance liquid chromatography</b>
<b>ICD-10</b>	:	<b>The tenth edition of the International Classification of Diseases and Related Health Problems</b>
<b>ICD-9</b>	:	<b>The ninth edition of the International Classification of Diseases</b>
<b>ICF</b>	:	<b>International classification of functioning disability and health</b>
<b>ID</b>	:	<b>Intellectual disability</b>
<b>IEP</b>	:	<b>Individualized education program</b>

<b>IQ</b>	<b>:</b>	<b>Intelligent quotient</b>
<b>ISCN</b>	<b>:</b>	<b>International system for cytogenetic nomenclature</b>
<b>IVF</b>	<b>:</b>	<b>In-vitro fertilization</b>
<b>MAOIs</b>	<b>:</b>	<b>Monoamine oxidase inhibitors</b>
<b>MAPH</b>	<b>:</b>	<b>Multiplex Amplifiable Probe Hybridization</b>
<b>MB-COMT</b>	<b>:</b>	<b>Membrane bound-COMT</b>
<b>MCA</b>	<b>:</b>	<b>Multiple congenital abnormalities</b>
<b>MDI</b>	<b>:</b>	<b>Mental developmental index</b>
<b>MR</b>	<b>:</b>	<b>Mental retardation</b>
<b>MRI</b>	<b>:</b>	<b>Magnetic resonance imaging</b>
<b>NOS</b>	<b>:</b>	<b>Not otherwise specified</b>
<b>NTM</b>	<b>:</b>	<b>Normal transmitting male</b>
<b>OR</b>	<b>:</b>	<b>Odds ratio</b>
<b>PCPID</b>	<b>:</b>	<b>President's Committee for People with Intellectual Disabilities</b>
<b>PCR-RFLP</b>	<b>:</b>	<b>Polymerase chain reaction restriction-fragment length polymorphism</b>
<b>PDI</b>	<b>:</b>	<b>Psychomotor development index</b>
<b>PFC</b>	<b>:</b>	<b>Prefrontal Cortex</b>
<b>PKU</b>	<b>:</b>	<b>Phenylketonuria</b>
<b>RE</b>	<b>:</b>	<b>Restriction enzyme</b>
<b>RT</b>	<b>:</b>	<b>Room temperature</b>
<b>SAH</b>	<b>:</b>	<b>S-adenosyl-homocysteine</b>
<b>SAM</b>	<b>:</b>	<b>S-adenosyl-methionine</b>
<b>S-COMT</b>	<b>:</b>	<b>Soluble-COMT</b>
<b>SMC</b>	<b>:</b>	<b>Supernumerary Marker Chromosome</b>
<b>SNP</b>	<b>:</b>	<b>Single Nucleotide Polymorphism</b>
<b>SQ</b>	<b>:</b>	<b>Social quotient</b>
<b>SSRIs</b>	<b>:</b>	<b>Serotonin selective reuptake inhibitors</b>
<b>TORCH</b>	<b>:</b>	<b>Toxoplasmosis, Rubella, CMV, Herpes simplex, Other infections</b>
<b>UG</b>	<b>:</b>	<b>Urogenital</b>
<b>VABs</b>	<b>:</b>	<b>Vineland adaptive behavior scale</b>
<b>VCFS</b>	<b>:</b>	<b>Velocardiofacial syndrome</b>
<b>VSD</b>		<b>Ventricular septal defect</b>
<b>WHO</b>	<b>:</b>	<b>World Health Organization</b>
<b>WISC-III</b>	<b>:</b>	<b>Wechsler Intelligence Scale 3<sup>rd</sup> edition</b>
<b>WPA</b>	<b>:</b>	<b>World Psychiatric Association</b>
<b>WPPSI-R</b>	<b>:</b>	<b>The Wechsler preschool and primary scale of intelligence-revised</b>

## **ABSTRACT**

Mental retardation (MR) remains one of the most lifelong handicaps. Chromosomal abnormalities are important cause of MR and they are usually combined with congenital anomalies. Catechol-O-methyltransferase (COMT) plays an important role in breakdown of dopamine in the prefrontal cortex and this is functionally related to individual intellectual ability. Two co-dominant alleles (G and A) in exon 4 of the COMT gene influence the amino acid structure (Val or Met) at codon 158. Therefore, the COMT enzyme activity is genetically polymorphic with trimodal distribution (high activity in Val/Val genotype, intermediate activity in Val/Met genotype, and low activity in Met/Met genotypes).

The current study was conducted on 40 mentally retarded patients with stigmata of dysmorphology and malformations to detect chromosomal abnormalities and to clarify the association between COMT gene polymorphism and intelligence quotient (IQ) level. They were classified into two groups. Group I: 26 patients (65%) with mild and moderate degree of MR (IQ: 35-70) and Group II: 14 patients (35%) with severe degree of MR (IQ: 20-34). All patients were subjected to full clinical examination, karyotyping by conventional GTG banding and assay of genetic polymorphism of catechol-O-methyltransferase by polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP). Association of MR with congenital anomalies was present in 70% of studied patients, 2.5% had major anomalies in the form of ventricular septal defect and minor anomalies were detected in 67.5% in the form of: eye abnormalities in 67%, mouth abnormalities in 60%, ear abnormalities in 55%, nose abnormalities in 52.5%, hand and skeletal abnormalities in 12.5%, speech delay in 20% and urogenital manifestations in 5% of the studied patients. 47.5% of the studied patients had more than three minor anomalies in the craniofacial region.

The results of karyotyping by conventional GTG banding revealed that 87.5% of the studied patients had normal karyotype and 12.5% had chromosomal abnormalities. Numerical chromosomal abnormalities were detected in 5% [(47,XY,+Marker in 2.5% and 47,XX,+Marker in 2.5%)], structural chromosomal abnormalities in 5% [(46,XX,del(9)(p22p24) in 2.5% and 46,XY,dup(22)(p11) in 2.5%] and sex chromosomal abnormalities in 2.5% ((46,XY,del(Y)(p11)).

The frequency of wild COMT (HH) genotype (55%) was the highest followed by heterozygous mutant (HL) genotype (37.5%) and homozygous mutant (LL) genotype (7.5%) i.e. the mutant COMT genotypes (HL,LL) were detected in 45% of the studied patients. The results of COMT genotyping by PCR-RFLP revealed that significantly higher mean IQ score in patients with wild (HH) genotype ( $42.1 \pm 8.9$ ) compared to those with mutant (HL, LL) genotypes ( $36.2 \pm 11.8$ )  $p$ -value = 0.14. It could be suggested that the association between COMT gene polymorphism and IQ level in MR is present, as the mutant COMT (HL, LL) genotypes showed an increased risk in reduction of IQ level. Odds ratio (OR) for IQ groups is 5.625, 95% confidence interval = 1.349-23.449. The results of this study need to be confirmed by subsequent studies investigating a larger number of patients in each group to avoid statistical interference and bias. More trials are needed to clearly delineate the magnitude of the role of COMT gene polymorphism in the pathogenesis of MR that might lead towards realistic therapies or preventive strategies for it.

**Keywords:**

Mental retardation, Chromosomal abnormalities, COMT polymorphism, Intelligence quotient

# *INTRODUCTION*

## **INTRODUCTION**

Mental retardation (MR) is a human mental disorder characterized by an Intelligence Quotient (IQ) score 70 or lower. Other life limitations include problems with communication, self care, social situations and school activities (**Zhang *et al.*, 2007**).

The incidence of MR is estimated currently around 1-3% of the population. Chromosomal abnormalities are an important cause of mental retardation and its frequency increased with the severity of the disease. 5-30% of moderate to severe MR can be accounted for by chromosomal disorders and the majority have associated with malformations, growth retardation, dysmorphism and family history of similar occurrence (**Lam *et al.*, 2006**).

The coexistence of neuropathology and cognitive deficits supports the view that MR is a result of genetic mutations in the degradation pathway and the release of neurotransmitters in the central nervous system CNS (**Zhang *et al.*, 2007**).

Dopamine is one of the most important neurotransmitters in human CNS, its levels are mediated by catechol-O-methyltransferase (COMT), this allows for critical modulation of cognitive function, especially in the prefrontal cortex (**Matsumoto *et al.*, 2003**).

Catechol-O-methyltransferase plays an important role in the metabolism of endogenous and drug catechols. COMT catalyzes the O-methylation of catechols by transferring the methyle group from S-adenosyl-L-methionine to one of the hydroxyl groups of the catecholmoiety. COMT substrate includes neurotransmitters such as norepinephrine, epinephrine, dopamine, catechole estrogens and catechole drugs (**Sharon and Cherie, 2009**).

COMT is encoded by a single gene localized on chromosome 22q 11.1-q11.2. Two co-dominant alleles (G and A) in exon 4 of the COMT gene influence the amino acid structure (Val or Met) at codon 158 (**Mathotra *et al.*, 2002**).

This single nucleotide polymorphism (SNP) is broadly referred to as Val 158 Met polymorphism (**Yirmi *et al.*, 2001**). Therefore, the COMT enzyme activity is genetically polymorphic with trimodal distribution (high activity in Val/Val genotype, intermediate activity in Val/Met genotype, and low activity in Met/Met genotypes).

COMT regulates dopamine degradation and is associated with psychosis, making it a promising candidate gene for studying MR (**Zhnag *et al.*, 2007**).